DE69022559T2 - Expression des rekombinanten Tumor-Nekrosisfaktor-Bindungsproteins I (TBP-I). - Google Patents
Expression des rekombinanten Tumor-Nekrosisfaktor-Bindungsproteins I (TBP-I).Info
- Publication number
- DE69022559T2 DE69022559T2 DE69022559T DE69022559T DE69022559T2 DE 69022559 T2 DE69022559 T2 DE 69022559T2 DE 69022559 T DE69022559 T DE 69022559T DE 69022559 T DE69022559 T DE 69022559T DE 69022559 T2 DE69022559 T2 DE 69022559T2
- Authority
- DE
- Germany
- Prior art keywords
- tbp
- binding protein
- necrosis factor
- tumor necrosis
- factor binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/55—Vector systems having a special element relevant for transcription from bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL9269789A IL92697A (en) | 1989-12-13 | 1989-12-13 | Molecular cloning of TNF binding protein |
IL95064A IL95064A0 (en) | 1990-07-12 | 1990-07-12 | Molecular cloning of tnf binding protein |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69022559D1 DE69022559D1 (de) | 1995-10-26 |
DE69022559T2 true DE69022559T2 (de) | 1996-05-02 |
Family
ID=26322015
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69022559T Expired - Lifetime DE69022559T2 (de) | 1989-12-13 | 1990-12-13 | Expression des rekombinanten Tumor-Nekrosisfaktor-Bindungsproteins I (TBP-I). |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0433900B1 (de) |
JP (1) | JPH0578396A (de) |
AT (1) | ATE128184T1 (de) |
AU (1) | AU642938B2 (de) |
CA (1) | CA2032191C (de) |
DE (1) | DE69022559T2 (de) |
DK (1) | DK0433900T3 (de) |
ES (1) | ES2080098T3 (de) |
GR (1) | GR3018123T3 (de) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL98078A0 (en) * | 1991-05-07 | 1992-06-21 | Yeda Res & Dev | Pharmaceutical compositions comprising an anticytokyne |
US5512544A (en) * | 1987-09-13 | 1996-04-30 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising an anticytokine |
IL83878A (en) * | 1987-09-13 | 1995-07-31 | Yeda Res & Dev | Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it |
US7264944B1 (en) | 1989-04-21 | 2007-09-04 | Amgen Inc. | TNF receptors, TNF binding proteins and DNAs coding for them |
ES2238070T3 (es) * | 1989-04-21 | 2005-08-16 | Amgen Inc. | Receptor del tnf, proteina ligante del tnf y adn codante para estos. |
US6221675B1 (en) | 1989-04-21 | 2001-04-24 | Amgen, Inc. | TNF receptors, TNF binding proteins and DNAs coding for them |
US6143866A (en) * | 1989-07-18 | 2000-11-07 | Amgen, Inc. | Tumor necrosis factor (TNF) inhibitor and method for obtaining the same |
IL95031A (en) | 1989-07-18 | 2007-03-08 | Amgen Inc | A method of producing a recombinant human necrotic factor absorber |
US6541610B1 (en) | 1989-09-05 | 2003-04-01 | Immunex Corporation | Fusion proteins comprising tumor necrosis factor receptor |
ATE236249T1 (de) * | 1989-09-12 | 2003-04-15 | Hoffmann La Roche | Tfn-bindende proteine |
US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
GB2246569A (en) * | 1990-06-15 | 1992-02-05 | Charing Cross Sunley Research | Tumour necrosis factor - alpha binding protein |
US5919452A (en) * | 1991-03-18 | 1999-07-06 | New York University | Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies |
US6284471B1 (en) | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
US7192584B2 (en) | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
US5698195A (en) * | 1991-03-18 | 1997-12-16 | New York University Medical Center | Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies |
US5656272A (en) * | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
IL99120A0 (en) * | 1991-08-07 | 1992-07-15 | Yeda Res & Dev | Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them |
JPH07508639A (ja) * | 1992-03-30 | 1995-09-28 | イミュネックス・コーポレーション | 腫瘍壊死因子受容体を含む融合蛋白質 |
US5795975A (en) * | 1993-01-10 | 1998-08-18 | Yeda Research And Development Co. Ltd. | TNF receptor promoter |
IL104355A (en) | 1993-01-10 | 2006-08-20 | Yeda Res & Dev | Tnf receptor promoter |
US5852173A (en) * | 1994-10-19 | 1998-12-22 | Genetics Institute, Inc. | TNF receptor death ligand proteins and inhibitors of ligand binding |
US5847099A (en) * | 1994-10-19 | 1998-12-08 | Genetics Institute, Inc. | TNF receptor death domain ligand proteins |
US5849501A (en) * | 1994-10-19 | 1998-12-15 | Genetics Institute, Inc. | TNF receptor death domain ligand proteins and method to identify inhibitors of ligand binding |
US5712381A (en) * | 1994-10-19 | 1998-01-27 | Genetics Institute, Inc. | MADD, a TNF receptor death domain ligand protein |
US5776746A (en) | 1996-05-01 | 1998-07-07 | Genitope Corporation | Gene amplification methods |
WO1997041244A1 (en) * | 1996-05-01 | 1997-11-06 | Genitope Corporation | Vaccines for treatment of lymphoma and leukemia |
TW555765B (en) | 1996-07-09 | 2003-10-01 | Amgen Inc | Low molecular weight soluble tumor necrosis factor type-I and type-II proteins |
PT942740E (pt) | 1996-12-06 | 2004-01-30 | Amgen Inc | Terapia de combinacao utilizando uma proteina de ligacao de tnf para tratamento de doencas mediadas por tnf |
ES2615357T3 (es) | 1996-12-06 | 2017-06-06 | Amgen Inc. | Terapia de combinación usando un inhibidor de IL-1 para tratar enfermedades mediadas por IL-1 |
US6287558B1 (en) | 1997-08-01 | 2001-09-11 | Biohybrio Technologies Llc | Devices containing cells or tissue and an agent that inhibits damage by a host cell molecule |
CN1082091C (zh) * | 1997-12-26 | 2002-04-03 | 中国人民解放军第二军医大学 | 重组人肿瘤坏死因子及制备方法 |
US6893838B1 (en) | 1998-04-07 | 2005-05-17 | Genetics Institute Llc | DADD, death activator death domain protein |
US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
AU4541101A (en) | 2000-03-02 | 2001-09-12 | Xencor Inc | Design and discovery of protein based tnf-alpha variants for the treatment of tnf-alpha related disorders |
UA81743C2 (uk) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
DK2270052T3 (en) | 2001-06-26 | 2018-07-02 | Amgen Inc | Antibodies to OPGL |
TWI334439B (en) | 2001-08-01 | 2010-12-11 | Centocor Inc | Anti-tnf antibodies, compositions, methods and uses |
US9028822B2 (en) | 2002-06-28 | 2015-05-12 | Domantis Limited | Antagonists against TNFR1 and methods of use therefor |
CA2511823A1 (en) | 2002-12-30 | 2004-07-22 | Amgen Inc. | Combination therapy with co-stimulatory factors |
WO2004098595A1 (en) * | 2003-05-12 | 2004-11-18 | Altana Pharma Ag | COMPOSITION COMPRISING ROFLUMILAST AND A TNFα ANTAGONIST |
US7892563B2 (en) | 2003-05-20 | 2011-02-22 | Wyeth Holdings Corporation | Methods for treatment of severe acute respiratory syndrome (SARS) |
WO2006018832A1 (en) * | 2004-08-18 | 2006-02-23 | Ares Trading S.A | Tnf-binding protein-1 in the treatment of psoriasis |
US7833527B2 (en) | 2006-10-02 | 2010-11-16 | Amgen Inc. | Methods of treating psoriasis using IL-17 Receptor A antibodies |
US8415291B2 (en) | 2008-10-31 | 2013-04-09 | Centocor Ortho Biotech Inc. | Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses |
TW201117824A (en) | 2009-10-12 | 2011-06-01 | Amgen Inc | Use of IL-17 receptor a antigen binding proteins |
DK3295957T3 (da) | 2010-01-15 | 2019-10-14 | Kirin Amgen Inc | Anti il-17ra-antistofformulering og terapeutiske regimener til behandling af psoriasis |
WO2013016220A1 (en) | 2011-07-22 | 2013-01-31 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
SG11201607881SA (en) | 2014-03-31 | 2016-10-28 | Kirin Amgen Inc | Methods of treating nail and scalp psoriasis |
US10465003B2 (en) | 2016-02-05 | 2019-11-05 | Janssen Biotech, Inc. | Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes |
MX2019008989A (es) | 2017-01-30 | 2019-10-09 | Janssen Biotech Inc | Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la artritis psoriasica activa. |
JP2020506947A (ja) | 2017-02-07 | 2020-03-05 | ヤンセン バイオテツク,インコーポレーテツド | 活動性強直性脊椎炎を治療するための抗tnf抗体、組成物、及び方法 |
US11780911B2 (en) | 2019-05-23 | 2023-10-10 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha |
-
1990
- 1990-12-13 AT AT90124133T patent/ATE128184T1/de not_active IP Right Cessation
- 1990-12-13 DE DE69022559T patent/DE69022559T2/de not_active Expired - Lifetime
- 1990-12-13 CA CA002032191A patent/CA2032191C/en not_active Expired - Lifetime
- 1990-12-13 ES ES90124133T patent/ES2080098T3/es not_active Expired - Lifetime
- 1990-12-13 DK DK90124133.1T patent/DK0433900T3/da active
- 1990-12-13 JP JP2419240A patent/JPH0578396A/ja active Pending
- 1990-12-13 EP EP90124133A patent/EP0433900B1/de not_active Expired - Lifetime
- 1990-12-13 AU AU68037/90A patent/AU642938B2/en not_active Expired
-
1995
- 1995-11-20 GR GR950403240T patent/GR3018123T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
CA2032191C (en) | 1999-05-18 |
DE69022559D1 (de) | 1995-10-26 |
AU6803790A (en) | 1991-06-20 |
JPH0578396A (ja) | 1993-03-30 |
EP0433900A1 (de) | 1991-06-26 |
GR3018123T3 (en) | 1996-02-29 |
EP0433900B1 (de) | 1995-09-20 |
CA2032191A1 (en) | 1991-06-14 |
ES2080098T3 (es) | 1996-02-01 |
AU642938B2 (en) | 1993-11-04 |
DK0433900T3 (da) | 1996-01-29 |
ATE128184T1 (de) | 1995-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE128184T1 (de) | Expression des rekombinanten tumor-nekrosisfaktor-bindungsproteins i (tbp-i). | |
LU90591I2 (fr) | Enbrel-etanercept | |
DE69033710T2 (de) | Sekretion vom mit Gamma-Interferon Signalpeptid gebundenen humänen Protein | |
PT101297A (pt) | Factores mitogenicos gliais, sua preparacao e utilizacao | |
MY102472A (en) | Preparation of funtional human urokinase proteins. | |
AU6250098A (en) | Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap02-l) | |
CA2121798A1 (en) | Novel cytokine | |
BR9708518A (pt) | Moduladores de fator associado a receptor tnf (traf) sua preparação e uso | |
ES2172502T3 (es) | Receptores tipo ii de interleucina 1. | |
ATE242322T1 (de) | Fusionsprotein , das zwei rezeptoren des tumornekrose-faktors enthält | |
DE69131580D1 (de) | GDF-1 und UOG1 Proteine | |
DE69841015D1 (de) | Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2 | |
ES8706827A1 (es) | Procedimiento para preparar polipeptidos. | |
ES2065915T3 (es) | Procedimiento para aumentar la expresion de polipeptidos en un cultivo de celula recombinante. | |
ZA95968B (en) | Interferon alpha/beta binding protein its preparation and use | |
ES547600A0 (es) | Procedimiento para preparar proteinas encarioticas, procarioticas o viricas. | |
ATE131175T1 (de) | Protein mit fibroblasten-wachstumsfaktor- rezeptoraktivität. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |